ZEGA Stock | | | EUR 67.00 0.50 0.75% |
AstraZeneca PLC
fundamentals help investors to digest information that contributes to AstraZeneca PLC's financial success or failures. It also enables traders to predict the movement of AstraZeneca Stock. The
fundamental analysis module provides a way to measure
AstraZeneca PLC's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various
microeconomic indicators and financial ratios related to AstraZeneca PLC stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to
Equity Screeners to view more equity screening tools.
AstraZeneca PLC Company Book Value Per Share Analysis
AstraZeneca PLC's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Current AstraZeneca PLC Book Value Per Share | | | | 11.95 X |
Most of AstraZeneca PLC's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AstraZeneca PLC is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
In accordance with the recently published financial statements, the book value per share of AstraZeneca PLC is about 11.949 times. This is 802.88% lower than that of the Healthcare sector and 7.16% lower than that of the
Drug Manufacturers - Major industry. The book value per share for all Germany stocks is 99.38% higher than that of the company.
| | Money Flow IndexDetermine momentum by analyzing Money Flow Index and other technical indicators |
AstraZeneca Fundamentals
About AstraZeneca PLC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AstraZeneca PLC's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AstraZeneca PLC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at
the intrinsic value of AstraZeneca PLC based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing
financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in AstraZeneca Stock
AstraZeneca PLC financial ratios help investors to determine whether AstraZeneca Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in AstraZeneca with respect to the benefits of owning AstraZeneca PLC security.